Melinta’s Kimyrsa (oritavancin) Receives the US FDA’s Approval for the Treatment of Acute Bacterial Skin and Skin Structure Infections

 Melinta’s Kimyrsa (oritavancin) Receives the US FDA’s Approval for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Melinta’s Kimyrsa (oritavancin) Receives the US FDA’s Approval for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Shots:

  • The approval is based on P-III SOLO trial involves assessing the safety, efficacy, and PK of Kimyrsa (qd, 1200 mg, IV dose, over 1 hour) vs vancomycin (1gm or 15 mg/kg, bid, over 3 hours) in 1,987 adults with ABSSSI
  • The 1EP and 2EP of the trial demonstrated that shorter infusion time and lower infusion volume of Kimyrsa is as effective as 7-to-10 days twice-daily vancomycin
  • Kimyrsa is a long-acting lipoglycopeptide antibiotic with rapid bactericidal activity for the treatment of adult patients with ABSSI caused by designated Gram-positive microorganisms, including MRSA and is expected to be available in the US in 2021

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post